315 related articles for article (PubMed ID: 17412302)
21. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation.
Avetisyan G; Aschan J; Hassan M; Ljungman P
Transplantation; 2008 Jul; 86(2):257-63. PubMed ID: 18645488
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases.
Elkayam O; Ablin J; Caspi D
Autoimmun Rev; 2007 Apr; 6(5):312-4. PubMed ID: 17412304
[TBL] [Abstract][Full Text] [Related]
23. Infections as triggers and complications of systemic lupus erythematosus.
Doria A; Canova M; Tonon M; Zen M; Rampudda E; Bassi N; Atzeni F; Zampieri S; Ghirardello A
Autoimmun Rev; 2008 Oct; 8(1):24-8. PubMed ID: 18703174
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.
Evison J; Farese S; Seitz M; Uehlinger DE; Furrer H; Mühlemann K
Clin Infect Dis; 2009 May; 48(10):1402-12. PubMed ID: 19361304
[TBL] [Abstract][Full Text] [Related]
25. Safety of vaccination of patients with systemic lupus erythematosus.
Abu-Shakra M
Lupus; 2009 Nov; 18(13):1205-8. PubMed ID: 19880569
[TBL] [Abstract][Full Text] [Related]
26. Systemic lupus erythematosus and vaccination.
Millet A; Decaux O; Perlat A; Grosbois B; Jego P
Eur J Intern Med; 2009 May; 20(3):236-41. PubMed ID: 19393490
[TBL] [Abstract][Full Text] [Related]
27. The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man.
Cox RJ; Haaheim LR; Ericsson JC; Madhun AS; Brokstad KA
Vaccine; 2006 Nov; 24(44-46):6577-80. PubMed ID: 16842889
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.
Pugès M; Biscay P; Barnetche T; Truchetet MÉ; Richez C; Seneschal J; Gensous N; Lazaro E; Duffau P
Rheumatology (Oxford); 2016 Sep; 55(9):1664-72. PubMed ID: 27160278
[TBL] [Abstract][Full Text] [Related]
29. Antibody response to influenza immunization in patients with systemic lupus erythematosus.
Mercado U
J Rheumatol; 2003 Oct; 30(10):2295; author reply 2295-6. PubMed ID: 14528534
[No Abstract] [Full Text] [Related]
30. [Recurrent aseptic meningitis following influenza vaccination in a case of systemic lupus erythematosus].
Ichikawa N; Takase S; Kogure K
Rinsho Shinkeigaku; 1983 Jul; 23(7):570-6. PubMed ID: 6661861
[No Abstract] [Full Text] [Related]
31. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
32. Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine.
Minke JM; Toulemonde CE; Dinic S; Cozette V; Cullinane A; Audonnet JC
J Comp Pathol; 2007 Jul; 137 Suppl 1():S76-80. PubMed ID: 17559865
[TBL] [Abstract][Full Text] [Related]
33. Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study.
Brydak LB; Romanowska M; Nowak I; Ciszewski A; Bilińska ZT
Med Sci Monit; 2009 Jul; 15(7):PH85-91. PubMed ID: 19564837
[TBL] [Abstract][Full Text] [Related]
34. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.
Danza A; Ruiz-Irastorza G
Lupus; 2013 Oct; 22(12):1286-94. PubMed ID: 24098001
[TBL] [Abstract][Full Text] [Related]
35. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
36. Immunosenescence of the equine immune system.
Horohov DW; Adams AA; Chambers TM
J Comp Pathol; 2010 Jan; 142 Suppl 1():S78-84. PubMed ID: 19897209
[TBL] [Abstract][Full Text] [Related]
37. Development of a vaccine against pandemic influenza viruses: current status and perspectives.
Ilyinskii PO; Thoidis G; Shneider AM
Int Rev Immunol; 2008; 27(6):392-426. PubMed ID: 19065349
[TBL] [Abstract][Full Text] [Related]
38. Lupus and vaccinations.
Mathian A; Pha M; Amoura Z
Curr Opin Rheumatol; 2018 Sep; 30(5):465-470. PubMed ID: 29889693
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
Arnoux S; Weinberger C; Gessner BD
Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
[TBL] [Abstract][Full Text] [Related]
40. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
